دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Editorial Board
doi : 10.1016/S0167-8140(21)06062-X
EDITORIAL BOARD| VOLUME 155, PII, FEBRUARY 01, 2021
A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy
Gargi Kothari,James Korte,Eric J. Lehrer,Tomas Kron,Nicholas Hardcastle,Shankar Siva
doi : 10.1016/j.radonc.2020.10.023
SYSTEMATIC REVIEW| VOLUME 155, P188-203, FEBRUARY 01, 2021
Radiomics allows extraction of quantifiable features from imaging. This study performs a systematic review and meta-analysis of the performance of radiomics based prognostic models in non-small cell lung cancer (NSCLC).
Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
G?rkem Türkkan,Yves Willems,Lizza E.L. Hendriks,Cristina Mitea,Stéphanie Peeters,Dirk De Ruysscher
doi : 10.1016/j.radonc.2020.11.020
REVIEW ARTICLE| VOLUME 155, P269-277, FEBRUARY 01, 2021
Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic lung disease with an unknown cause. Uncertainties still remain regarding the pathogenesis of IPF, and the prognosis of this disease is poor despite some recent improvements in treatment. Radiation induced lung injury (RILI) is a common complication and a dose-limiting toxicity of thoracic radiotherapy. Importantly, IPF is a crucial risk factor for pulmonary toxicity after thoracic radiotherapy. Although IPF is not universally accepted as a definite contraindication for thoracic radiotherapy at present, it has been shown that IPF can increase the risk of severe and fatal complications after thoracic radiotherapy. Proton beam therapy has shown promising results in reducing the incidence of thoracic radiotherapy related life-threatening complications in IPF patients, but the current evidence is not sufficient to recommend the standard use of it. Many similarities are noticeable between IPF and RILI in terms of pathogenesis and underlying mechanisms. Better understanding of the mechanisms of IPF and RILI may enable clinicians to provide safer and more effective thoracic radiotherapy treatments in cancer patients with IPF. In this review, we summarize the current knowledge of IPF, present the importance of IPF in radiation oncology practice, and highlight the similarities and relationship between IPF and RILI.
Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial)
Sweet Ping Ng,Julie Chu,Sarat Chander,Alexander Heriot,Michael Michael,Samuel Y. Ngan
doi : 10.1016/j.radonc.2020.10.012
ORIGINAL ARTICLE| VOLUME 155, P27-32, FEBRUARY 01, 2021
The chemotherapy exposure during chemoradiotherapy for rectal cancer is adequate for radiosensitization but suboptimal for treatment of distant micrometastasis. This study aimed to determine tolerability, dose intensity, response, and toxicity of a novel intensified neoadjuvant treatment approach.
Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)
Nai-Bin Chen,Qi-Wen Li,Su Li,Nan Hu,Bo Qiu,Hui Liu
doi : 10.1016/j.radonc.2020.10.035
ORIGINAL ARTICLE| VOLUME 155, P105-112, FEBRUARY 01, 2021
This phase I trial aimed to determine the maximal tolerated dose (MTD) of incorporating a twice-weekly docetaxel and nedaplatin regimen into definitive concurrent chemoradiotherapy (CCRT) as radiosensitizers in patients with inoperable esophageal squamous cell carcinoma (ESCC).
Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer
B.G. Wortman,E. Astreinidou,M.S. Laman,C.L. Creutzberg,R.A. Noutfor the PORTEC Study Group
doi : 10.1016/j.radonc.2020.10.038
ORIGINAL ARTICLE| VOLUME 155, P160-166, FEBRUARY 01, 2021
The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence.
Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial
Katsumi Hirose,Akiyoshi Konno,Junichi Hiratsuka,Yasuhiro Kikuchi,Masao Murakami,Yoshihiro Takai
doi : 10.1016/j.radonc.2020.11.001
ORIGINAL ARTICLE| VOLUME 155, P182-187, FEBRUARY 01, 2021
Boron neutron capture therapy (BNCT) can be performed without reactors due to development of cyclotron-based epithermal neutron source (C-BENS), which is optimized for treatment for deeper-seated tumors. The purpose of this study was to evaluate efficacy and safety of cyclotron-based BNCT with borofalan (10B) for recurrent or locally advanced head and neck cancer.
A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome
M.A. Teriaca,M. Loi,M. Suker,F.A.L.M. Eskens,C.H.J. van Eijck,J.J. Nuyttens
doi : 10.1016/j.radonc.2020.11.006
ORIGINAL ARTICLE| VOLUME 155, P232-236, FEBRUARY 01, 2021
Purpose: To report the long-term outcome of a multicenter phase II study with FOLFIRINOX followed by stereotactic body radiotherapy (LAPC-1 trial) in patients with locally advanced pancreatic cancer (LAPC). Materials and methods: Patients with histological confirmation of LAPC inoperable at diagnosis were enrolled. Induction therapy with 8 cycles of FOLFIRINOX was administered. If no disease progression was found after chemotherapy, patients received stereotactic body radiotherapy (SBRT) at a total dose of 40 Gy in 5 fractions. Results: In LAPC-1 trial, 50 patients were included, but due to disease progression in 11 patients under chemotherapy, 39 patients received stereotactic SBRT after FOLFIRINOX treatment. In whole population, the 1- and 3-year overall survival (OS) were 62% and 10%, respectively. Median follow-up was 13 months. The SBRT group had median OS of 18 months (95% CI 13.2-21.5) versus 5 months (95% CI 4.1-6.7) in non-SBRT group (p<0.001). After chemoradiotherapy, seven patients underwent surgery achieving a radical resection. Patients who underwent surgery had a 3-years OS of 43% compared to 6.5% in the unresected group (p=0.03). Four patients developed grade ? 3 adverse events during SBRT. Conclusions: Long-term survival has been found in patients with LAPC underwent FOLFIRINOX followed by SBRT. This approach increased the probability of a radical surgery. The resected patients achieved a significant better survival compared to unresected group.
Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial
Aurelie Garant,Petr Kavan,André-Guy Martin,Carole Richard,Gerald Batist,Té Vuong
doi : 10.1016/j.radonc.2020.11.008
ORIGINAL ARTICLE| VOLUME 155, P237-245, FEBRUARY 01, 2021
Randomized studies have shown low compliance to adjuvant chemotherapy in rectal cancer patients receiving preoperative chemotherapy and external beam radiation (CT/EBRT) with total mesorectal excision. We hypothesize that giving neoadjuvant CT before local treatment would improve CT compliance.
18F-FDG-PET in guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours: A phase I study (FiGaRO)
A. Michaelidou,D. Adjogatse,Y. Suh,S. Barrington,M. Lei,T. Guerrero Urbano
doi : 10.1016/j.radonc.2020.10.039
ORIGINAL ARTICLE| VOLUME 155, P261-268, FEBRUARY 01, 2021
The FiGaRO trial assessed the feasibility and safety of using an FDG-PET-based dose-painting technique to deliver a radiotherapy (RT) boost?to the FDG-avid primary tumour in patients with locally advanced high and intermediate risk oropharyngeal cancer.
SPARC, a phase-I trial of pre?operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer
Daniel L.P. Holyoake,Maxwell Robinson,Michael Silva,Ganesh Radhakrishna,Somnath Mukherjee,Maria A. Hawkins
doi : 10.1016/j.radonc.2020.11.007
ORIGINAL ARTICLE| VOLUME 155, P278-284, FEBRUARY 01, 2021
Following resection of pancreatic cancer, risk of positive margins and local recurrence remain high, especially for borderline-resectable pancreatic cancer (BRPC). We aimed to establish the maximum tolerated dose of a margin-intensified five-fraction stereotactic body radiotherapy (SBRT) regimen designed to treat the region at risk.
Development of staffing, workload and infrastructure in member departments of the European Organisation for Research and Treatment of Cancer (EORTC) radiation oncology group
Jonas Willmann,Philip Poortmans,Angelo Fillipo Monti,Nick Reynaert,Coen W. Hurkmans,Nicolaus Andratschke
doi : 10.1016/j.radonc.2020.11.009
ORIGINAL ARTICLE| VOLUME 155, P226-231, FEBRUARY 01, 2021
The EORTC Radiation Oncology Group uses a Facility Questionnaire (FQ) to collect information from its member radiation oncology departments. We analysed the FQ database for patient-related workload, staffing levels and infrastructure to determine developments in radiation oncology departments in the clinical trials community.
Hypofractionated radiation therapy for breast cancer: Preferences amongst radiation oncologists in Europe – Results from an international survey
Ivica Ratosa,Monica Emilia Chiril?,Mateja Steinacher,Radovan Vojt??ek,Pierfrancesco Franco,Philip Poortmans
doi : 10.1016/j.radonc.2020.10.008
ORIGINAL ARTICLE| VOLUME 155, P17-26, FEBRUARY 01, 2021
We aimed to assess the prescription preference about hypofractionated radiation therapy (HFRT) for breast cancer (BC) patients amongst radiation oncologists (ROs) practicing in Europe and to identify restraints on HFRT utilisation.
Dosimetric parameters associated with radiation-induced esophagitis in breast cancer patients undergoing regional nodal irradiation
Alexander Yaney,Ahmet S. Ayan,Xueliang Pan,Kayla Tedrick,Julia R. White,Jose G. Bazan
doi : 10.1016/j.radonc.2020.10.042
ORIGINAL ARTICLE| VOLUME 155, P167-173, FEBRUARY 01, 2021
Rates of acute esophagitis in breast cancer patients undergoing regional nodal irradiation (RNI) are under-reported. We set to identify esophageal dose–volume constraints associated with grade 2 esophagitis (G2E). We hypothesized that the G2E rate was higher with intensity modulated radiation therapy (IMRT) vs. 3D conformal radiation therapy (3DCRT).
Prediction of pseudoprogression and long-term outcome of vestibular schwannoma after Gamma Knife radiosurgery based on preradiosurgical MR radiomics
Huai-Che Yang,Chih-Chun Wu,Cheng-Chia Lee,Wan-Yuo Guo,Yu-Te Wu,Chia-Feng Lu
doi : 10.1016/j.radonc.2020.10.041
ORIGINAL ARTICLE| VOLUME 155, P123-130, FEBRUARY 01, 2021
Gamma Knife radiosurgery (GKRS) is a safe and effective treatment modality with a long-term tumor control rate over 90% for vestibular schwannoma (VS). However, numerous tumors may undergo a transient pseudoprogression during 6–18 months after GKRS followed by a long-term volume reduction. The aim of this study is to determine whether the radiomics analysis based on preradiosurgical MRI data could predict the pseudoprogression and long-term outcome of VS after GKRS.
A qualitative classification signature for post-surgery 5-fluorouracil-based adjuvant chemoradiotherapy in gastric cancer
Meifeng Li,Haifeng Chen,Jun He,Yidan Shi,Zheng Guo,Haidan Yan
doi : 10.1016/j.radonc.2020.10.011
ORIGINAL ARTICLE| VOLUME 155, P65-72, FEBRUARY 01, 2021
Currently, 5-fluorouracil (5-FU)-based adjuvant chemoradiotherapy (ACRT) is a preferred regimen for post-surgery gastric cancer (GC). However, the survival outcome of 5-FU-based ACRT varies greatly among different GC patients. Thus, it is necessary to classify which patients may benefit from 5-FU-based ACRT.
Patient-reported outcomes after external beam radiotherapy versus brachytherapy for palliation of dysphagia in esophageal cancer: A matched comparison of two prospective trials
Peter S.N. van Rossum,Paul M. Jeene,Tom Rozema,Maarten C.C.M. Hulshof,Peter D. Siersema,Sherif Y. El Sharouni
doi : 10.1016/j.radonc.2020.10.009
ORIGINAL ARTICLE| VOLUME 155, P73-79, FEBRUARY 01, 2021
A matched comparison of external beam radiotherapy (EBRT) versus brachytherapy recently demonstrated that EBRT appears at least as effective for palliating dysphagia in patients with incurable esophageal cancer. The aim of this analysis was to compare patient-reported outcomes (PROs) after EBRT versus brachytherapy.
Definitive radiotherapy for prostate cancer in Norway 2006–2015: Temporal trends, performance and survival
Sophie D. Foss?,Kirsti Aas,Christoph. Müller,Johanne Gulbrandsen,Erik Haug,Tor A. Myklebust
doi : 10.1016/j.radonc.2020.10.022
ORIGINAL ARTICLE| VOLUME 155, P33-41, FEBRUARY 01, 2021
More studies are needed to document nation-wide use and effectiveness of curative definitive radiotherapy (Def-RT) in the treatment of prostate cancer (PCa).
Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy
William H. Smith,Jamie Cesaretti,Chih Peng Chin,Mitchell Terk,Richard G. Stock
doi : 10.1016/j.radonc.2020.10.021
ORIGINAL ARTICLE| VOLUME 155, P42-47, FEBRUARY 01, 2021
We sought to describe the safety and efficacy of salvage low dose rate (LDR) brachytherapy for local prostate cancer recurrence following definitive RT.
Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study
Matthew G. Parry,Julie Nossiter,Thomas E. Cowling,Heather Payne,Jan van der Meulen,Ajay Aggarwal
doi : 10.1016/j.radonc.2020.10.019
ORIGINAL ARTICLE| VOLUME 155, P48-55, FEBRUARY 01, 2021
Little is known about the functional outcomes and health-related quality of life (HRQoL) following external beam radiation therapy (EBRT) combined with a high-dose rate brachytherapy boost (EBRT-BB) for the treatment of prostate cancer. We aimed to compare patient-reported outcomes of EBRT to those of EBRT-BB.
Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study
H. Wang,L.C. Mendez,G. Morton,M.R. Downes,D. Vesprini,S.K. Liu
doi : 10.1016/j.radonc.2020.10.029
SHORT COMMUNICATION| VOLUME 155, P80-85, FEBRUARY 01, 2021
This exploratory study evaluates immunological changes in high-risk Gleason 9 prostate cancer patients treated with EBRT+BT compared to EBRT alone. Notably, BT demonstrates the potential to elicit a T cell response which may support further investigation using circulating immune cells as predictive and prognostic biomarkers for radiotherapy response.
Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma
William R. Grubb,Lee Ponsky,Simon S. Lo,Sanjay Gupta,Mitchell Machtay,Rodney J. Ellis
doi : 10.1016/j.radonc.2020.10.031
ORIGINAL ARTICLE| VOLUME 155, P138-143, FEBRUARY 01, 2021
We previously demonstrated the safety of doses up to 48 Gy in 4 fractions with stereotactic body radiotherapy (SBRT) in poor surgical candidates with localized renal cell carcinoma (RCC). In an additional expansion cohort, we aimed to assess the safety of further dose escalation to 48–60 Gy in 3 fractions.
Early alteration in apparent diffusion coefficient and tumor volume in cervical cancer treated with chemoradiotherapy or radiotherapy: Incremental prognostic value over pretreatment assessments
Yui Watanabe,Satoshi Nakamura,Yasutaka Ichikawa,Tomoaki Ikeda,Yoshihito Nomoto,Hajime Sakuma
doi : 10.1016/j.radonc.2020.09.059
ORIGINAL ARTICLE| VOLUME 155, P3-9, FEBRUARY 01, 2021
Our study aimed to evaluate a prognostic value of early changes in apparent diffusion coefficients (ADC) and tumor volume during treatment in patients with cervical cancer treated with chemoradiotherapy or radiotherapy, and to assess whether the early changes provided an incremental value to pre-treatment ADC and tumor volume in predicting disease recurrences.
Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer – Have we identified all the risk factors?
Joshua L. Rodr?guez-L?pez,Diane C. Ling,Andrew Keller,Adrianna E. Mojica-M?rquez,Scott M. Glaser,Sushil Beriwal
doi : 10.1016/j.radonc.2020.10.010
ORIGINAL ARTICLE| VOLUME 155, P86-92, FEBRUARY 01, 2021
Ureteral stenosis (US) is a known complication from image-guided brachytherapy (IGBT); however, no dosimetric parameter has been associated with ureteral toxicity. We aimed to report the rate of late grade ?3 US after MRI-based IGBT, and to identify clinical factors and dosimetric parameters predictive for US.
Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network
Supriya Chopra,Akshay Mangaj,Alisha Sharma,Kari Tanderup,Richard Potter,Remi A Nout
doi : 10.1016/j.radonc.2020.10.037
ORIGINAL ARTICLE| VOLUME 155, P151-159, FEBRUARY 01, 2021
In the metastatic or recurrent cervical cancer, systemic chemotherapy constitutes the main treatment. Though there is an increasing use of high dose external radiation and brachytherapy in the metastatic setting, no consensus exists.
Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
Wei-Jie Luo,Wen-Qing Zou,Shao-Bo Liang,Ai-Hua Lin,Jun Ma,Yan-Ping Mao
doi : 10.1016/j.radonc.2020.10.005
ORIGINAL ARTICLE| VOLUME 155, P56-64, FEBRUARY 01, 2021
In the intensity-modulated radiotherapy (IMRT) era, the role of concurrent chemoradiotherapy (CCRT) after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LANPC) is undetermined, while concerns exist about CCRT-associated excessive toxicity. We aimed to combine tumor response and risk assessment to guide decisions about concurrent chemotherapy.
CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy
Benjamin S. Rosen,Joel R. Wilkie,Yilun Sun,Christina H. Chapman,Avraham Eisbruch,Michelle L. Mierzwa
doi : 10.1016/j.radonc.2020.10.006
ORIGINAL ARTICLE| VOLUME 155, P174-181, FEBRUARY 01, 2021
To assess associations between imaging biomarkers from standard of care pre-treatment CT and FDG-PET scans and locoregional (LR) and distant metastatic (DM) recurrences in patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiotherapy (CRT).
Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma
Shao-Bo Liang,Lu-Si Chen,Xing-Li Yang,Chuan-Bo Xie,Li-Zhi Liu,Xiang-Ying Xu
doi : 10.1016/j.radonc.2020.11.011
ORIGINAL ARTICLE| VOLUME 155, P219-225, FEBRUARY 01, 2021
To assess the impact of tumor necrosis on treatment sensitivity and long-term survival in patients with nasopharyngeal carcinoma (NPC) treated using intensity-modulated radiation therapy (IMRT).
Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer
V. Bourbonne,R. Da-ano,V. Jaouen,D. Visvikis,M. Hatt,U. Schick
doi : 10.1016/j.radonc.2020.10.040
ORIGINAL ARTICLE| VOLUME 155, P144-150, FEBRUARY 01, 2021
(Chemo)–radiotherapy (RT) is the gold standard treatment for patients with locally advanced lung cancer non accessible for surgery. However, current toxicity prediction models rely on clinical and dose volume histograms (DVHs) and remain unsufficient. The goal of this work is to investigate the added predictive value of the radiomics approach applied to dose maps regarding acute and late toxicities in both the lungs and esophagus.
The impact of stereotactic body radiation therapy on the overall survival of patients diagnosed with early-stage non-small cell lung cancer
Saber A. Amin,Morshed Alam,Michael J. Baine,Chi Zhang,Ibur Rahman,Chi Lin
doi : 10.1016/j.radonc.2020.10.028
ORIGINAL ARTICLE| VOLUME 155, P254-260, FEBRUARY 01, 2021
Stereotactic Body Radiotherapy (SBRT) has emerged as a standard treatment for inoperable early-stage non-small cell lung cancer (NSCLC) with remarkable local control. However, it is not clear if this local control translates to overall survival (OS). The objective of this study is to investigate the impact of SBRT on the OS of early-stage NSCLC patients and examine if the extent of this impact changes with the era of diagnosis, T stage, age, and comorbidity status.
Towards homogenization of total body irradiation practices in pediatric patients across SIOPE affiliated centers. A survey by the SIOPE radiation oncology working group
Bianca A.W. Hoeben,Montserrat Pazos,Michael H. Albert,Stéphane Supiot,Marc Bierings,Geert O. Janssens
doi : 10.1016/j.radonc.2020.10.032
ORIGINAL ARTICLE| VOLUME 155, P113-119, FEBRUARY 01, 2021
To reduce relapse risk, Total Body Irradiation (TBI) is part of conditioning regimens for hematopoietic stem cell transplantation (HSCT) in pediatric acute leukemia. The study purpose was to evaluate clinical practices regarding TBI, such as fractionation, organ shielding and delivery techniques, among SIOPE affiliated radiotherapy centers.
Regional lymph node irradiation in locally advanced Merkel cell carcinoma reduces regional and distant relapse and improves disease-specific survival
Neal Andruska,Lily Mahapatra,Randall J. Brenneman,Brian C. Baumann,Wade L. Thorstad,Mackenzie D. Daly
doi : 10.1016/j.radonc.2020.11.003
ORIGINAL ARTICLE| VOLUME 155, P246-253, FEBRUARY 01, 2021
One-third of patients with Merkel cell carcinoma (MCC) present with locally advanced disease involving the regional lymph nodes, but indications for regional lymph node radiation therapy (rLN-RT) are not well established.
MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose
Jeremy Booth,Vincent Caillet,Adam Briggs,Carol Haddad,Thomas Eade,Paul Keall
doi : 10.1016/j.radonc.2020.10.036
no discription
The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions.
Current delivery limitations of proton PBS for FLASH
Wei Zou,Eric S. Diffenderfer,Keith A. Cengel,James M. Metz,BoonKeng K. Teo,Lei Dong
doi : 10.1016/j.radonc.2020.11.002
ORIGINAL ARTICLE| VOLUME 155, P212-218, FEBRUARY 01, 2021
Proton Pencil Beam Scanning (PBS) is an attractive solution to realize the advantageous normal tissue sparing elucidated from FLASH high dose rates. The mechanics of PBS spot delivery will impose limitations on the effective field dose rate for PBS.
Identification of the mutation signature of the cancer genome caused by irradiation
Shun-Ichiro Kageyama,Junyan Du,Syuzo Kaneko,Masaki Nakamura,Katsuya Tsuchihara,Tetsuo Akimoto
doi : 10.1016/j.radonc.2020.10.020
ORIGINAL ARTICLE| VOLUME 155, P10-16, FEBRUARY 01, 2021
Ionising radiation causes mutations in the genomes of tumour cells and serves as a potent treatment for cancer. However, the mutation signatures in the cancer genome following ionising radiation have not been documented.
Genistein inhibits radiation-induced invasion and migration of glioblastoma cells by blocking the DNA-PKcs/Akt2/Rac1 signaling pathway
Xiongxiong Liu,Qiqi Wang,Bingtao Liu,Pengcheng Zhang,Weiqiang Chen,Qiang Li
doi : 10.1016/j.radonc.2020.10.026
ORIGINAL ARTICLE| VOLUME 155, P93-104, FEBRUARY 01, 2021
Radiotherapy is the most important therapeutic measure against glioblastoma multiforme (GBM), which is regarded as the most common and highly lethal type of brain cancer. Nevertheless, most relapses originate in the close vicinity of the irradiated target volume. Genistein is a natural product that can suppress the invasive potential of cancer cells. In this study, DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-proficient and -deficient GBM cells were selected for in vitro and in vivo studies to investigate the inhibiting effects of genistein on radiation-induced invasion and migration and the corresponding mechanism.
Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial
Antje Dietrich,Michael Andreeff,Lydia Koi,J?rg Kotzerke,Michael Baumann,Mechthild Krause
doi : 10.1016/j.radonc.2020.11.013
ORIGINAL ARTICLE| VOLUME 155, P285-292, FEBRUARY 01, 2021
Systemic molecular radiotherapy utilizes internal irradiation by radionuclide-labeled tumor-targeting agents with the potential to destroy (micro-)metastases. However, doses that are applicable in solid tumors do not reach the levels nessecary for tumor control. Thus, the combination of molecular and external radiotherapy is a promising treatment strategy, as enhanced tumor doses can be delivered with and without minor overlapping toxicities. Here, we combined a 90Y-labeled anti-EGFR antibody (Cetuximab) with clinically relevant fractionated radiotherapy in a preclinical trial using head and neck squamous cell carcinoma xenograft tumors.
Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma
Mathieu Sertorio,Ali Nowrouzi,Mahdi Akbarpour,Amir Abdollahi,Yi Zheng,Susanne I. Wells
doi : 10.1016/j.radonc.2020.10.024
ORIGINAL ARTICLE| VOLUME 155, P293-303, FEBRUARY 01, 2021
Knowledge of biological responses to proton therapy (PT) in comparison to X-ray remains in its infancy. Identification of PT specific molecular signals is an important opportunity for the discovery of biomarkers and synergistic drugs to advance clinical application. Since PT is used for the treatment of lymphoma, we report here transcriptomic responses of lymphoma cell lines to PT vs X-ray and identify potential therapeutic targets.
Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer
Sebastian Zschaeck,Klaus Z?phel,Annekatrin Seidlitz,Esther G.C. Troost,Steffen L?ck,Mechthild Krause
doi : 10.1016/j.radonc.2020.10.030
ORIGINAL ARTICLE| VOLUME 155, P204-211, FEBRUARY 01, 2021
Positron emission tomography (PET) is a functional imaging modality which is able to deliver tracer specific biological information, e.g. about glucose uptake, inflammation or hypoxia of tumors. We performed a proof-of-principle study that used different tracers and expanded the analytical scope to non-tumor structures to evaluate tumor-host interactions.
Effect of radiotherapy interruption due to COVID-19 outbreak
Dongdong Yu,Weiguo Hu,Lulu Chen,Zhenming Fu,Qibin Song,Xiangpan Li
doi : 10.1016/j.radonc.2020.09.055
COVID-19 RAPID LETTER| VOLUME 155, P1-2, FEBRUARY 01, 2021
COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2
Barbara Alicja Jereczek-Fossa,Matteo Pepa,Mattia Zaffaroni,Renzo Corv?,Vittorio Donatoon behalf of on the behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)
doi : 10.1016/j.radonc.2020.09.049
COVID-19 RAPID LETTER| VOLUME 155, P120-122, FEBRUARY 01, 2021
Magnetic resonance imaging guided brachytherapy: Time for non-pelvic cancer? Example of tongue brachytherapy
Alexandre Escande,Frederic Crop,Xavier Liem,Sophie El Bedoui,Eric Felix Lartigau,Abel Cordoba
doi : 10.1016/j.radonc.2020.07.049
LETTER TO THE EDITOR| VOLUME 155, E1-E2, FEBRUARY 01, 2021
Response to Escande et al.: Magnetic guided brachytherapy: Time for non-pelvic cancer? Example from tongue brachytherapy [1]
Gy?rgy Kov?cs,Rafael Martinez-Monge,Ashwini Budrukkar,Frank-André Siebert,Luca Tagliaferrion behalf of the GEC-ESTRO Head & Neck and Skin Working Group
doi : 10.1016/j.radonc.2020.07.047
LETTER TO THE EDITOR| VOLUME 155, E3-E4, FEBRUARY 01, 2021
Professional quality of life, burnout and alexithymia
Santosh K. Chaturvedi
doi : 10.1016/j.radonc.2020.08.017
LETTER TO THE EDITOR| VOLUME 155, E5, FEBRUARY 01, 2021
In response to Chaturvedi: Professional quality of life, burnout and alexithymia
Valentina Tesio,Lorys Castelli,Pierfrancesco Franco
doi : 10.1016/j.radonc.2020.08.020
LETTER TO THE EDITOR| VOLUME 155, E6-E7, FEBRUARY 01, 2021
Response letter: Letter to the editor regarding Wei W et al.: ‘‘Experience of the Hubei cancer hospital in Wuhan, China”
Jianping Bi,Wei Wei,Desheng Hu,Guang Han
doi : 10.1016/j.radonc.2020.08.030
LETTER TO THE EDITOR| VOLUME 155, E8-E9, FEBRUARY 01, 2021
Radionecrosis: Pandora’s box
Yasemin Bolukbasi,Yavuz Samanci,Eyub Yasar Akdemir,Selcuk Peker
doi : 10.1016/j.radonc.2020.07.058
LETTER TO THE EDITOR| VOLUME 155, E10, FEBRUARY 01, 2021
In response to Bolukbasi et al
Nikhil T. Sebastian,Daniel Trifiletti,Paul D. Brown,Michael Chan,Joshua D. Palmer
doi : 10.1016/j.radonc.2020.09.006
LETTER TO THE EDITOR| VOLUME 155, E11-E12, FEBRUARY 01, 2021
Comment on: Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients, by Onal C et al.
Shikha Goyal,Renu Madan
doi : 10.1016/j.radonc.2020.09.031
LETTER TO THE EDITOR| VOLUME 155, E13-E14, FEBRUARY 01, 2021
In response to Goyal et al.
Cem Onal
doi : 10.1016/j.radonc.2020.09.030
LETTER TO THE EDITOR| VOLUME 155, E15, FEBRUARY 01, 2021
Letter to the editor of radiotherapy and oncology regarding the article “Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan” by Demizu et al.
Fu-Sheng Liu,Fu-Bing Liu,Qian-Shi Zhang,Xiao-Bin Wang,Ming-Xiang Zou,Jing Li
doi : 10.1016/j.radonc.2020.11.017
LETTER TO THE EDITOR| VOLUME 155, E16-E17, FEBRUARY 01, 2021
In response to Liu et al
Yusuke Demizu,Reiko Imai,Hiroki Kiyohara,Takashi Nakano,Tadashi Kamadathe Japan Carbon-Ion Radiation Oncology Study Group
doi : 10.1016/j.radonc.2020.11.016
LETTER TO THE EDITOR| VOLUME 155, E18-E19, FEBRUARY 01, 2021
In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy
Filippo Alongi,Stefano Arcangeli,Francesco Cuccia,Marta Scorsetti,Renzo Corv?,Stefano Maria Magrini
doi : 10.1016/j.radonc.2020.11.034
LETTER TO THE EDITOR| VOLUME 155, E20-E21, FEBRUARY 01, 2021
In reply to the letter to the editor: “In reply to Fiorino et al: The central role of the radiation oncologist in the multidisciplinary and multiprofessional model of modern radiation therapy”
Claudio Fiorino,Robert Jeraj,Catharine H. Clark,Wouter van Elmpt,Thomas Bortfeld,Nuria Jornet
doi : 10.1016/j.radonc.2020.12.033
LETTER TO THE EDITOR| VOLUME 155, E22-E23, FEBRUARY 01, 2021
